Badawod Eman
Clinical Immunology and Allergy, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
SAGE Open Med Case Rep. 2025 Jul 13;13:2050313X251357053. doi: 10.1177/2050313X251357053. eCollection 2025.
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster (Pfizer-BioNTech). The patient initially presented with a generalized erythematous rash, which progressed despite treatment with topical and systemic corticosteroids. He later developed tense blisters and peripheral eosinophilia, with a skin biopsy confirming the diagnosis of bullous pemphigoid. Although bullous pemphigoid has previously been linked to various vaccinations, the underlying mechanisms remain uncertain. Notably, cases of bullous pemphigoid flare-ups have been reported in patients with existing bullous pemphigoid after receiving mRNA COVID-19 vaccines. This report underscores the importance of considering new-onset bullous pemphigoid in patients presenting with blistering skin conditions following COVID-19 vaccination.
大疱性类天疱疮被认为是最常见的自身免疫性水疱性皮肤病。本报告介绍了加拿大一名54岁男性的病例，该患者在接种第五剂新冠病毒疫苗加强针（辉瑞-BioNTech）4周后出现新发大疱性类天疱疮。患者最初表现为全身性红斑疹，尽管接受了局部和全身皮质类固醇治疗，但仍有进展。他后来出现紧张性水疱和外周嗜酸性粒细胞增多，皮肤活检确诊为大疱性类天疱疮。虽然大疱性类天疱疮此前已与多种疫苗接种有关，但其潜在机制仍不确定。值得注意的是，已有报告称，现有大疱性类天疱疮患者在接种mRNA新冠病毒疫苗后出现病情复发。本报告强调了在新冠病毒疫苗接种后出现皮肤水疱症状的患者中考虑新发大疱性类天疱疮的重要性。
